Hologic, Inc. (NASDAQ:HOLX) Shares Sold by ING Groep NV

ING Groep NV cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 71.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,121 shares of the medical equipment provider’s stock after selling 82,283 shares during the period. ING Groep NV’s holdings in Hologic were worth $2,698,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares during the period. Swedbank AB acquired a new stake in shares of Hologic during the first quarter valued at approximately $120,827,000. Black Creek Investment Management Inc. lifted its position in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Hologic by 1,023.3% in the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the period. Finally, Marshall Wace LLP acquired a new position in Hologic in the 2nd quarter worth approximately $39,427,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 1.4 %

Hologic stock opened at $78.60 on Friday. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The company’s fifty day moving average price is $80.71 and its two-hundred day moving average price is $78.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the firm posted $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HOLX shares. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday. UBS Group upped their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Raymond James raised their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.